ANGIODYNAMICS INC (ANGO)
Health Care · Interventional vascular devices and atherectomy systems · NASDAQ
AngioDynamics develops minimally invasive vascular intervention devices for treating peripheral artery disease, thrombosis, and cancer, anchored by its proprietary Auryon laser atherectomy platform.
What ANGIODYNAMICS INC does
AngioDynamics is a diversified medical technology company that designs, manufactures, and sells products for treating cardiovascular disease and cancer. The company operates across two segments—Med Tech and Med Device—offering innovative solutions including laser atherectomy systems (Auryon), thrombectomy devices, venous drainage systems, and related interventional tools. The company has built its portfolio through organic development and strategic acquisitions, with manufacturing primarily in Queensbury, New York.
Themes: peripheral artery disease (PAD) / atherectomy, thrombectomy / thrombus management, venous drainage and extracorporeal bypass, interventional radiology, minimally invasive vascular intervention, cancer treatment
Fundamentals
- Price$15.75 as of 2026-08-21 close
- Market cap$651M as of 2026-08-21
- 1-year return+73.6% 2025-08-21 close $9.07 → 2026-08-21 close $15.75
- P/En/a negative earnings
- Net margin-11.5% as of 2026-08-24
- Gross margin+54.6% as of 2026-08-24
- ROE-21.0% as of 2026-08-24
- Debt / equity0.03 as of 2026-08-24
- Revenue growth (YoY)+9.5% as of 2026-08-24
- Revenue CAGR (3y)-1.9% SEC XBRL
- Beta0.28 as of 2026-08-24
- Last reported earnings2026-07-14 SEC EDGAR Form 8-K (Item 2.02)
How ANGO compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ANGIODYNAMICS INC looks technically
ANGIODYNAMICS INC (ANGO) is trading 30.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 39 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative). It made a new 20-day high about 3 trading days ago. It is 3.3% below its 52-week high (its highest price of the past year). Trading volume is unusually light — only about 28% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 30.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +30.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $13.94 | $13.94 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.05 | $12.05 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 13.79. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 39 trading days ago — a "golden cross", a bullish long-term signal | 39 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with buyers in control | 39.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 65, neither overbought (above 70) nor oversold (below 30) | 64.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($14.83 to $16.29) — its "stochastic" reading is 63 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 63.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 4 trading days ago (its momentum flipped negative) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.29 | $16.29 |
|---|---|---|
| From the 52-week high | it is 3.3% below its 52-week high (its highest price of the past year) | -3.3% |
| Above the 52-week low | it is 82.1% above its 52-week low (its lowest price of the past year) | +82.1% |
| Below the 52-week high | it is 3.3% below its highest point of the past year | 3.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $32.00 (set on 2021-11-05) | $32.00 |
| Given back of the 52-week move | over the past year its closes ranged ($8.78 to $16.07), and it has given back only a small part of its rise from last year’s low — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $11.33 to $11.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 4.4% |
| From the all-time high | it is 50.8% below its all-time high | -50.8% |
| Nearest price level | it is trading 11.8% above a support level at $13.90 — a price it turned at three times since 2025-12-04, most recently on 2026-06-26. Since 2024-08-21 it has 18 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -11.8% |
| All-time low | its lowest closing price on record is $5.26 (set on 2024-03-25) | $5.26 |
| Above the all-time low | it is 199.4% above its all-time low | +199.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 51st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5117 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5117 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $14.10 and $16.53 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $14.10 – $15.31 – $16.53 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 7.2 daily ranges above its 200-day average price (30.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 28% of its 30-day average | 0.28× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Gap filled | a 6.8% gap up opened on 2026-07-14 has been "filled" 28 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 28 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -1.99% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 8.4 percentage points (the stock gained 10.8% while the market gained 2.3%) | +8.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 28.6 percentage points (the stock gained 31.7% while the market gained 3.1%) | +28.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 29.3 percentage points (the stock gained 40.4% while the market gained 11.1%) | +29.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 53.2 percentage points (the stock gained 73.6% while the market gained 20.5%) | +53.2% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.1% of the share price. | +16.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $11.85 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +33.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-07-14 (its 10-K), so the typical buyer over that stretch is showing a gain. That average is $14.65 — a volume-weighted average of daily closes over 29 sessions, not a true tick-by-tick VWAP. | +7.5% |
Price levels it has turned at before
ANGO last closed at $15.75 on 2026-08-21. Since 2024-08-21 it has turned at 18 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.90 | Support | 11.8% below the last close | turned there three times · 2025-12-04 to 2026-06-26 |
| $13.44 | Support | 14.7% below the last close | turned there twice · 2025-01-30 to 2026-01-05 |
| $13.07 | Support | 17.0% below the last close | turned there twice · 2025-01-08 to 2025-12-12 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $13.79.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $14.21 and $15.21 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $16.11.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$20.00 range $17.00 – $24.00; median $19.50
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ANGO
- Consensus EPS estimate-$0.1133 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company is currently unprofitable with a negative net margin of -10%, burning cash in operations and facing pressure to achieve profitability while growing revenue","Reliance on FDA clearances and international regulatory approvals for product sales; changes in regulatory requirements or delays in approvals could impact commercialization timelines","Significant debt servicing obligations and declining cash position (cash fell from $55.9M to $37.8M in nine months ended Feb 2026) constrains financial flexibility for R&D and growth investments"]
What changed in the latest 10-Q
AI-assisted comparison of ANGO's 10-Q filed 2026-04-02 against the prior one filed 2026-01-06.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number changed from 21 (older filing, 2026-01-06) to 22 (newer filing, 2026-04-02) at end of Executive Overview section
- Notes:
- Both filings appear to be truncated at the same point ('In evaluating the operating performance of our business, managemen'), making full comparison of the complete MD&A section impossible
- The visible text content is substantively identical between the two filings except for the page number change
- The page number difference likely reflects document pagination and does not indicate substantive content changes in the compared sections
Risk Factors
- Added:
- Newer filing (2026-04-02) presents nine-month period ended Feb 28, 2026 vs. older filing (2026-01-06) presenting six-month period ended Nov 30, 2025
- Newer filing includes third quarter data (three months ended Feb 28, 2026) with net sales of $78,423 thousand
- Newer filing reports nine-month net sales of $233,567 thousand vs. older filing six-month net sales of $155,144 thousand
- Newer filing nine-month net loss of $(25,337) thousand vs. older filing six-month net loss of $(17,253) thousand
- Newer filing includes balance sheet as of Feb 28, 2026 with cash of $37,810 thousand vs. older filing balance sheet as of Nov 30, 2025 with cash of $41,638 thousand
- Newer filing cash flows statement covers nine months ended Feb 28, 2026 vs. older filing covering six months ended Nov 30, 2025
- Newer filing shows stockholders' equity balance at Feb 28, 2026 of $173,357 thousand vs. older filing at Nov 30, 2025 of $176,333 thousand
- Newer filing includes consolidated statement of stockholders' equity extending through Feb 28, 2026 with additional quarterly data
- Removed:
- Older filing quarterly comparison data (three months ended Nov 30, 2025 vs. Nov 30, 2024) not present in newer filing
- Older filing balance sheet as of Nov 30, 2025 replaced with Feb 28, 2026 balance sheet
- Older filing cash flows for six months ended Nov 30, 2025 vs. Nov 30, 2024 replaced with nine months ended Feb 28, 2026 vs. Feb 28, 2025
- Reworded:
- Consolidated Statements of Operations header changed from 'Six Months Ended' to 'Nine Months Ended'
- Consolidated Statements of Comprehensive Loss header changed from 'Six Months Ended' to 'Nine Months Ended'
- Balance sheet dates changed from 'Nov 30, 2025' to 'Feb 28, 2026'
- Cash flows statement header changed from 'Six Months Ended' to 'Nine Months Ended'
- Stockholders' equity statement extended to include quarter ended Feb 28, 2026 with corresponding net loss of $(8,084) thousand
- Notes:
- The two filings represent different reporting periods (nine months vs. six months), making direct period-to-period financial metric comparisons not equivalent
- Comparison is limited to Item 1A through Item 6 headers and financial statements sections provided; full Risk Factors narrative content not included in either source text
- Balance sheet and financial metrics differences reflect different measurement dates rather than changes in disclosure
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($344006) — 1 selling insider
- Last 90 days0 buys · 1 sell ($344006) — 1 selling insider
- Last 180 days0 buys · 1 sell ($344006) — 1 selling insider
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of ANGO within a 30-day window between 2025-10-09 and 2025-10-21. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-30. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ANGO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 3 matched disclosures for ANGO from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ANGO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,982,815
- Reported value $68,024,606
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ANGO had 1,221,837 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ANGO had 2.96% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.52 days to cover at the same settlement.
- Reported short interest (shares) 1,221,837
- Short interest (% of shares outstanding) 2.96%
- Prior settlement (shares) 1,315,694
- Reported change -7.13%
- Days to cover (reported) 2.52
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Boston Scientific (BSX)
- Medtronic (MDT)
- Stryker (SYK)
- LivaNova (LIVN)
- Merit Medical Systems
- Spectranetics/Philips
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ANGO vs…
Frequently asked questions
What does ANGIODYNAMICS INC (ANGO) do?
AngioDynamics is a diversified medical technology company that designs, manufactures, and sells products for treating cardiovascular disease and cancer. The company operates across two segments—Med Tech and Med Device—offering innovative solutions including laser atherectomy systems (Auryon), thrombectomy devices, venous drainage systems, and related interventional tools.
What sector is ANGIODYNAMICS INC (ANGO) in?
ANGIODYNAMICS INC (ANGO) is classified in the Health Care sector. Its industry is Interventional vascular devices and atherectomy systems. It trades on NASDAQ.
Who are ANGIODYNAMICS INC's (ANGO) competitors?
Notable peers of ANGIODYNAMICS INC (ANGO) include Boston Scientific, Medtronic, Stryker, LivaNova and Merit Medical Systems. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ANGO?
Yes — we hold 3 matched STOCK Act disclosures for ANGO from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ANGIODYNAMICS INC (ANGO) overbought or oversold right now?
ANGIODYNAMICS INC (ANGO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 65, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ANGO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.